Kovitz Investment Group Partners LLC lifted its holdings in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Free Report) by 66.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 25,000 shares of the company’s stock after purchasing an additional 10,000 shares during the period. Kovitz Investment Group Partners LLC’s holdings in Taysha Gene Therapies were worth $79,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently modified their holdings of the business. Capital Investment Advisors LLC acquired a new position in Taysha Gene Therapies in the third quarter valued at $32,000. AQR Capital Management LLC acquired a new position in shares of Taysha Gene Therapies during the second quarter valued at about $38,000. Maven Securities LTD acquired a new position in shares of Taysha Gene Therapies during the fourth quarter valued at about $34,000. Bank of New York Mellon Corp bought a new position in shares of Taysha Gene Therapies during the 3rd quarter worth about $82,000. Finally, Commonwealth Equity Services LLC boosted its holdings in Taysha Gene Therapies by 44.0% in the third quarter. Commonwealth Equity Services LLC now owns 26,971 shares of the company’s stock worth $85,000 after acquiring an additional 8,246 shares in the last quarter. Institutional investors and hedge funds own 25.91% of the company’s stock.
Taysha Gene Therapies Trading Up 7.7 %
NASDAQ:TSHA opened at $1.68 on Monday. Taysha Gene Therapies, Inc. has a 52 week low of $0.50 and a 52 week high of $3.89. The firm has a 50-day moving average price of $1.63 and a two-hundred day moving average price of $2.02.
Insider Transactions at Taysha Gene Therapies
In other news, major shareholder Paul B. Manning acquired 100,000 shares of the company’s stock in a transaction that occurred on Friday, November 17th. The shares were acquired at an average price of $1.63 per share, for a total transaction of $163,000.00. Following the completion of the purchase, the insider now owns 16,566,667 shares in the company, valued at $27,003,667.21. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 2.25% of the company’s stock.
Analysts Set New Price Targets
Separately, Cantor Fitzgerald restated an “overweight” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a report on Monday, December 18th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $5.71.
Taysha Gene Therapies Profile
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.
- Five stocks we like better than Taysha Gene Therapies
- How Technical Indicators Can Help You Find Oversold Stocks
- Uber quadruples EPS estimates, but is growth decelerating?
- How to Invest in Communication Stocks
- 3 stocks set to benefit from record Valentine’s Day spending
- There Are Different Types of Stock To Invest In
- Tradeweb is a disruptive pure play on financial market liquidity
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.